研究单位：[1]Pfizer[2]UC Irvine Health,Orange,California,United States,92868-3201[3]The First affiliated Hospital of Anhui Medical University,Hefei,Anhui,China,230022[4]Beijing Chest Hospital, Capital Medical University,Beijing,Beijing,China,100000[5]Beijing Cancer Hospital,Beijing,Beijing,China,100142[6]Fujian Cancer Hospital,Fuzhou,Fujian,China,350014[7]Guangdong Provincial People's Hospital,Guangzhou,Guangdong,China,510080[8]Hunan Cancer Hospital,Changsha,Hunan,China,410006[9]General Hospital of Eastern Theater Command,Nanjing,Jiangsu,China,210002[10]The first hospital of jilin university,Changchun City,Jilin,China,130021[11]Jilin Cancer Hospital,Changchun,Jilin,China,130000[12]Sir Run Shaw Hospital,Hangzhou,Qiantang District,China,310016[13]The Second Affiliated Hospital of PLA Air Force Medical University,Xi'an City,Shaanxi,China,710038[14]Shanghai Chest Hospital,Shanghai,Shanghai,China,200030[15]Sichuan Cancer Hospital,Chengdu,Sichuan,China,610000[16]The First Affiliated Hospital Zhejiang University School of Medicine,Hangzhou,Zhejiang,China,310003[17]The Second Affiliated Hospital of Zhejiang University College of Medicine,Hangzhou,Zhejiang,China,310009[18]Zhejiang Cancer Hospital,Hangzhou,Zhejiang,China,310022[19]University Cancer Hospital,Beijing,China,100000[20]Beijing Chest Hospital, Capital Medical University,Beijing,China,101149[21]Fudan University Shanghai Cancer Center,Shanghai,China,200032[22]CHU de Rennes - Hôpital Pontchaillou,Rennes,France,35033[23]Institut Gustave Roussy,Villejuif Cedex,France,94805[24]Healthcare Global Enterprises,Bengaluru,Karnataka,India,560027[25]Bhakti Vedanta Hospital & Research Institute,Thane/Mumbai,Maharashtra,India,401107[26]Aichi Cancer Center Hospital,Nagoya,Aichi,Japan,464-8681[27]National University Hospital,Singapore,Singapore,119074[28]National Cancer Centre Singapore,Singapore,Singapore,168583[29]National Cancer Centre Singapore,Singapore,Singapore,169610[30]Hospital Vall D´Hebron,Barcelona,Cataluña,Spain,08035[31]Hospital Universitari Vall d'Hebron,Barcelona,Spain,08035[32]National Taiwan University Hospital,Taipei,Taiwan,10002
The purpose of this protocol is to provide continued treatment access and safety follow-up for eligible participants who continue to derive a benefit from study intervention in the Pfizer sponsored lorlatinib parent studies that will be closed. Additional follow-up safety data collection will permit further characterization of the safety profile of lorlatinib in participants continuing to receive study intervention
